Valeant Weighs Takeover of Salix in Latest Pharma Contest

Valeant Pharmaceuticals International Inc. is exploring a takeover of Salix Pharmaceuticals Ltd., people with knowledge of the matter said, in the wake of the U.S. drugmaker’s recent inventory-accounting restatement and management shakeup.

The Canadian drugmaker has discussed its interest with advisers, said the people, who asked not to be identified because the talks are private. Salix has a market value of about $9 billion, after its shares rose 5 percent to $140.47 in New York trading.